Zoladex
Kennedy's Disease
Ramathibodi HospitalPhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Kennedy's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
AVOLVE National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | B |
Same molecule, other indications
Zoladex is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →